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Abstract 
Background: Repeat renal biopsies in patients with lupus nephritis (LN) are usually 
performed to guide treatment or to establish disease chronicity. Their value is not 
clear from available literature. There is also no available data in Africa to guide 
clinicians. 
Methods: This was a retrospective study of patients undergoing a repeat renal 
biopsy between January 2003 and December 2014 from a single centre in Cape 
Town, South Africa. Relevant demographic, clinical and histological records of 
patients with repeat renal biopsies were documented. Comparison of data from 1st 
and 2nd renal biopsy was performed.  
Results: 44 patients had at least 2 biopsies performed during the study period. Most 
patients were females (81. 8%). The mean biopsy interval was 2.8±1.8 years. 
Proteinuria was the main indication for repeat biopsy (36.1%). The glomerular 
filtration rate and proteinuria worsened between the two biopsies (p=0.001 and 
0.019) respectively suggesting disease progression. Most patients (65.4%) with a 
non-proliferative class of LN at first biopsy progressed into a proliferative class 
whereas patients with initial proliferative LN at first biopsy (77.8%) remained as 
proliferative at repeat biopsy. Treatment was changed in 85% of patients at second 
biopsy.  
Conclusion: Repeat renal biopsies in patients with LN presents a useful means of 
assessing disease progression and provides guidance regarding modification of 
treatment. More studies are however required to evaluate the value of repeat 





Chapter 1: Structured Literature review 




















1.0 Objectives of the Literature review 
1.To give a broad overview of what is known about Systemic Lupus Erythematosus
(SLE) and Lupus Nephritis (LN) from the published literature and International society 
guidelines. 
2.To put into context what is already known about LN globally in an African
perspective. 
3.To identify important studies on repeat renal biopsies performed to date.
4.To Identify clinical relevance of repeat renal biopsies, if any, from the published
literature 
2.0 Broad Overview of SLE 
2.1 Epidemiology  
Systemic lupus erythematosus (SLE) is a chronic multi system autoimmune disease 
characterised by frequent remissions and relapses. The pattern of disease that 
dominates during the first few years of illness normally prevails throughout the 
course of disease.1 
Women are nine times more affected than males.2 The reported prevalence of SLE 
is 20 to 150 cases per 100,000 in United States of America.3 However the disease is 
said to be  rare in West Africa with  increasing frequency in Central and Southern 
Africa.4 Highest prevalence of the disease is reported  in people of African descent 
living in America, the Caribbean and Europe.5  
This prevalence gradient is thought to be related to: 
a) Racial admixture.4 In Cape Town, South Africa  for example SLE is reported more
frequently in patients of mixed ancestry.6
b) Increased exposure to environmental factors like tobacco products and viral
infections.7
c) Genetic polymorphisms like in the Fc gamma RIIb that offer protection to malaria
may increase susceptibility to SLE in Africans and Asians.8
The reported incidence and Prevalence of SLE in Africa is thought to be largely 
underestimated because of under diagnosis due to poor access to health care, low 
disease recognition within primary health care settings, limited access to diagnostic 
tools and inadequate numbers of specialist physicians.9,10 
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2.2 Diagnosis of SLE 
Patients are classified as having SLE if they meet the new classification criteria, 
Systemic Lupus International Collaborating Clinics (SLICC) criteria which has 
improved sensitivity compared to the old ACR criteria.11 (Table 1) The presence of 
clinical features of nephritis raises suspicions of LN which should be confirmed on 
histology.  
Table 1: SLICC Classification Criteria for SLE11 
Requires 4 or more criteria (at least 1 clinical and 1 laboratory criteria) 
Clinical Criteria Immunological Criteria 
1.Acute cutaneous Lupus 1.ANA 
2.Chronic cutaneous Lupus 2.Anti-DNA 
3.Oral or Nasal ulcers 3.Anti-Sm 
4.Non-Scarring alopecia 4.Antiphospholipid Antibody 
5.Arthritis 5.Low complement (C3, C4, CH50) 
6.Serositis 6.Direct Coombs test 
7.Renal involvement  
8.Neurologicinvolvement  
9.Haemolytic Anaemia  
10.Leukopaenia  
11.Thrombocytopaenia(<100 000/mm3)  
 
 
2.3 Clinical Presentation 
SLE may go on for many months and possibly years undetected due to the presence 
of vague constitutional symptoms such as fever and malaise. This can result in 
delayed diagnosis therefore constituting an unmet need in patients with SLE.12 A high 
index of suspicion is therefore needed in patients without typical features to avoid 
late presentation with irreversible end-organ damage.  
Table 2 shows the various clinical presentations based on a study of 1000 European 
SLE Patients and another study from South Africa with 226 patients with SLE.13,14 The 







Table 2: Prevalence of clinical features in patients with LN 
*nr=not reported 
3.0 Kidney involvement in SLE 
3.1 - Defining kidney disease in SLE 
The presence of Lupus Nephritis(LN) should be considered in any lupus patient with 
impaired kidney function, proteinuria, hypertension, or an active urine sediment 
according to KDIGO guidelines.15 
An active sediment include presence of haematuria, leukocytes, red blood cell casts 
and white blood cell casts. Kidney involvement is specifically defined as persistent 
proteinuria (>0.5 g/24 h) or presence of cellular red cell casts by the SLICC criteria.11 
 However LN must be confirmed by kidney biopsy because the histologic findings 
provide the basis for treatment recommendations for LN.15 A large study in Cape 
Town actually found out that most patients with LN will present with the 
proliferative form of the disease (Class III and IV) making it imperative to make an 
early diagnosis.6  
SLE Manifestation Euro Lupus cohort (%) 
 Cervera et al 13 
N=1000 
 
SA Cohort (%) 
Wadee et al14 
N=226 
Arthritis 84 70.4 
Malar Rash 58 58.4 
Fever 52 *nr 
Photosensitivity 45 38.9 
Nephropathy 39 43.8 
Serositis 36 18.1 
Raynaud’s Phenomenon 34 nr 
Neurologic Involvement 27 15.9 
Oral ulcers 24 38.5 
Thrombocytopenia 22 12.8 
Sicca Syndrome 16 nr 
Livedo Reticularis 14 nr 
Thrombosis 14 nr 
Lymphadenopathy 12 nr 
Discoid Lesions 10 41.5 
Myositis 9 nr 
Haemolytic Anaemia 8 nr 
Lung Involvement 7 Nr 
Subcutaneous Lesions  6 nr 
Chorea 2 nr 
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The clinical presentation of LN varies from asymptomatic haematuria and/or 
proteinuria to nephrotic syndrome and rapidly progressive glomerulonephritis with 
loss of renal function. In South Africa, Nephrotic range proteinuria is a very common 
initial presentation.16 In a study of 251 patients with LN, proteinuria was reported to 
be positively correlated with proliferative LN in SA.6 Urinalysis therefore presents an 
early opportunity for early diagnosis, for example LN must be strongly suspected in 
any SLE patient with high titres of dsDNA and a positive dipstick for blood.6,10 
 
3.2 LN a challenging problem in Africa and Globally 
Lupus nephritis is the commonest secondary glomerular disease reported in South 
Africa and other parts of the world.16-18 This is further supported by a recent 
systematic review from Africa which found LN and Hepatitis B to be commonest 
causes of secondary glomerular diseases.19 An estimated 25–50% of SLE patients will 
have urinary abnormalities or decline in renal function in the early course of the 
disease with up to 60% of adults and 80% of children with SLE developing renal 
abnormalities in the latter course of the disease.20 There is good evidence that renal 
involvement in SLE is associated with reduced quality of life and increased morbidity 
and mortality.21 In the Euro Lupus Project, which had 1000 patients with SLE from 
several European countries that were followed prospectively from 1991,renal 
involvement was reported to be 39%.13 In South Africa the reported prevalence is 
slightly higher (43%).14 However much higher prevalence of LN have been reported 
in other parts of Africa, 49,5% in North Africa in a study of 749 patients and up to 
70% in Zimbabwe.22,23  
 
3.3 Clinical Course of LN  
The presence of the following factors on initial presentation has been shown in many 
studies to predict poor outcomes in LN.24-27: 
➢ Elevated serum creatinine 
➢ Hypertension 
➢ Nephrotic range proteinuria 
➢ Anaemia  




In South Africa, Ayodele et al reported that baseline serum creatinine and failure of 
remission in the first year were associated with poor renal outcomes in patients with 
biopsy proven LN.28 In another study from South Africa, 50% of patients with 
proliferative LN reached the composite end point of doubling of creatinine, ESRD or 
death.29 This is possibly  explained by a high prevalence of APOL1 gene risk alleles in 
LN patients of African ancestry, which has been found to be a risk for faster CKD 
progression and ESRD.30 
Once SLE patients develop LN their outcomes are worse than those with no kidney  
involvement suggesting that LN is a manifestation of a more severe form of SLE. The  
reported mortality of SLE in Africa is very high, in a study from South Africa for 
 example about 72% of patients were either dead or lost to follow up after 55 months  
and nephritis was the only predictor of mortality on multivariate analysis.14 
 
3.4  Classification of kidney disease in SLE 
LN is classified using a new classification system (ISN/RPS,Table 3) which is an  
improvement of the old modified WHO system.31,32 It allows standardisation of  
definitions and emphasise clinically relevant lesions making comparability easier  
between centers.33The ISN classification system divides glomerular disorders into six  
different patterns (or classes) based upon kidney biopsy histopathology.32 It is  












Class I  Minimal mesangial lupus nephritis  




Class II  Mesangial proliferative lupus nephritis  
Purely mesangial hyper cellularity of any degree or mesangial matrix expansion by light 
microscopy, with mesangial immune deposits 
A few isolated sub-epithelial or sub endothelial deposits may be visible by 
immunofluorescence or electron microscopy, but not by light microscopy 
   
Class III  Focal lupus nephritis  
  Active or inactive focal, segmental or global endo- or extra capillary glomerulonephritis 
involving <50% of all glomeruli, typically with focal sub endothelial immune deposits, with or 
without mesangial alterations 
         III (A) Active lesions: focal proliferative lupus nephritis 
         III (A/C) Active and chronic lesions: focal proliferative and sclerosing lupus nephritis 
         III (C) Chronic inactive lesions with glomerular scars: focal sclerosing lupus nephritis 
   
Class IV  Diffuse lupus nephritis  
  Active or inactive diffuse, segmental or global endo- or extra capillary glomerulonephritis 
involving 50% of all glomeruli, typically with diffuse sub endothelial immune deposits, with 
or without mesangial alterations. This class is divided into diffuse segmental (IV-S) lupus 
nephritis when 50% of the involved glomeruli have segmental lesions, and diffuse global (IV-
G) lupus nephritis when 50% of the involved glomeruli have global lesions. Segmental is 
defined as a glomerular lesion that involves less than half of the glomerular tuft. This class 
includes cases with diffuse wire loop deposits but with little or no glomerular proliferation. 
         IV-S (A) Active lesions: diffuse segmental proliferative lupus nephritis 
         IV-G (A) Active lesions: diffuse global proliferative lupus nephritis 
         IV-S (A/C) Active and chronic lesions: diffuse segmental proliferative and sclerosing lupus nephritis 
         IV-G (A/C) Active and chronic lesions: diffuse global proliferative and sclerosing lupus nephritis 
         IV-S (C) Chronic inactive lesions with scars: diffuse segmental sclerosing lupus nephritis 
         IV-G (C) Chronic inactive lesions with scars: diffuse global sclerosing lupus nephritis 
  
Class V  Membranous lupus nephritis  
  Global or segmental sub epithelial immune deposits or their morphologic sequelae by light 
microscopy and by immunofluorescence or electron microscopy, with or without mesangial 
alterations 
  Class V lupus nephritis may occur in combination with class III or IV in which case both will be 
diagnosed 
  Class V lupus nephritis may show advanced sclerosis 
 
Class VI  Advanced sclerotic lupus nephritis  
  90% of glomeruli globally sclerosed without residual activity 
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5.0 - Treatment of lupus nephritis 
The 2003 ISN/RPS classification of LN allows for standardization of treatment. The 
aim of treatment is to achieve a complete remission (CR) or partial remission(PR) 
because this is associated with improved outcomes compared with no response.35 
The recommended treatment regimens are summarized in Table 4 and 5 and briefly 
discussed below:  
5.1 General measures-For all patients 
a) Aggressive antihypertensive control with the goal blood pressure less than 140/90
mmHg if no albuminuria but 130/80 in the presence of albuminuria.36,37 
b) In patients with proteinuria, antiproteinuric therapy with an ACEI or ARB and goal
protein excretion is less than 500 mg per day or at least 60 percent below baseline.38 
c) All patients with SLE regardless of disease activity should be treated with
hydroxychloroquine or chloroquine unless contraindicated.10 Hydroxychloroquine 
and chloroquine has been shown to reduce constitutional symptoms, 
musculoskeletal manifestations, flare rates, thrombotic events, organ damage 
accrual and mortality.39,40 
5.2 Immunosuppressive Treatment 
Patients with proliferative LN should be pulsed with steroids and started on 
cyclophosphamide or mycophenolate mofetil (MMF) as part of induction 
treatment10,15 This is then followed by maintenance treatment with MMF or 
Azathioprine with low doses of steroids.10,15 There is no consensus on the duration 
of maintenance though at least 1 year is generally advised.15 In South Africa the 
practise  is  to give maintenance treatment for at least 2 years.10  
A modified National Institute of Health Study (NIH) protocol is used in South Africa 
instead.10 Cyclophosphamide cheaper than MMF, hence MMF is reserved to those 
intolerant or have failed induction with cyclophosphamide. However, this may 
change as generics become easily available. 
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The oral Cyclophosphamide regimen is not favoured because it is associated with 
longer treatment duration, greater cumulative doses and more severe leucopenia.41 
• The Euro Lupus regimen which uses less doses of cyclophosphamide is not 
favoured in Africa where the disease is much more severe compared to the 
population in the Euro Lupus study.10,29,42 
 
Table 4: Recommended Induction treatment for Proliferative LN.15 
 




0.5-1 g/m2 monthly for 6 months 
Euro-Lupus Regimen IV Cyclophosphamide 500mg every 2 weeks for 3 months 
Oral Cyclophosphamide Regimen 1 -1.5mg/kg per day 
150mg max per day for 2-4 months 
MMF regimen MMF up to 3g/d for 6 months 
All regimens IV Methylprednisolone in severe cases followed by oral 
prednisolone 0.5-1mg/kg tapered over 6 to 12 months 













Table 5: Treatment of Non-Proliferative Lupus Nephritis.15 
 
 
6.0 - Flare of lupus nephritis 
6.1- Definition of a lupus flare 
A flare or relapse is a measurable increase in disease activity in one or more organ 
systems involving new or worse clinical findings, laboratory measurements or 
changes in activity of daily living.15 It must be considered clinically significant and 
usually there would be consideration of an increase in treatment. Appendix 9. 
6.2 - Predicting Flares in Lupus Nephritis 
As high as 20% of patients with LN can have a new kidney flare per year of  
follow-up.43 Even in patients who achieve CR , as much as 40% will experience a  
kidney relapse within a median of 41 months after remission.44 
Increased serum anti-dsDNA antibodies and low complement especially CH50, C3, 
and C4 can be useful in predicting lupus flares.43,45 Recently anti-C1q was found to 
have higher correlation with flares of LN than other serum markers.46  Increased 
proteinuria, an active urine sediment, a rise in creatinine or a fall in eGFR can also be 
used to identify a flare.15 
Class Recommendation 
I Treatment as dictated by the extra renal clinical 
manifestations of lupus. 
II <1g proteinuria: Treatment as dictated by the extra renal clinical manifestations of 
lupus 
>3g proteinuria: Corticosteroids or Calcineurin Inhibitors 
V Normal kidney function and non–nephrotic range 
Proteinuria: antiproteinuric and antihypertensive medications, and only receive 
corticosteroids and immunosuppressive as dictated by the extra renal 
manifestations lupus. 
Persistent nephrotic proteinuria: Corticosteroids plus an additional 
immunosuppressive agent: cyclophosphamide or Calcineurin inhibitor or MMF  
VI Treatment as dictated by the extra renal clinical 




6.3 Limitation of Clinical and Serological Markers in Predicting flares 
The challenge in managing lupus flares is that none of these biomarkers can replace 
renal histology and indeed it is quite possible to have significant renal activity on 
biopsy in the absence of heavy proteinuria or an active urine sediment.47 
Standard clinical and laboratory parameters have limited predictive values for 
discriminating between active LN and chronic disease.48 Thus, serological markers of 
disease activity do not adequately reflect the amount of renal inflammation in LN 
and cannot replace renal biopsy as a diagnostic and predictive tool for active disease. 
Therefore clinical and laboratory features alone are often not sufficient to guide 
treatment hence the need for renal biopsies.49-51 Therefore a renal biopsy is 
considered as the gold standard for assessing renal activity and hence defining the 
need for a change in treatment.15 
 
7.0 - Renal biopsies in Lupus Nephritis  
7.1- Diagnostic Role 
In patients with SLE a renal biopsy is recommended in the following 
circumstances.15,52: 
1.Protein excretion greater than 500 mg/day. 
2.An active urinary sediment (haematuria, cellular casts). 
3.A rising serum creatinine that is not clearly attributable to another mechanism. 
In those patients with an indication for renal biopsy it is important for the procedure 







7.2 Repeat renal biopsy strategy: Protocol Vs Repeat biopsy after a flare  
There is often need to repeat renal biopsies in patients treated for LN due to the 
limitations of clinical and laboratory measures described earlier. There are two 
strategies employed in performing repeat kidney biopsies: 
• Protocol biopsies at end of induction or maintenance treatment to assess 
treatment efficacy and need for more immunosuppression.48,55-60 
• Repeat renal biopsies only after a clinically suspected flare to assist in 
making treatment choices.15,61-65 
There is no consensus on which practice is superior and clinical practice varies 
from centre to centre with most clinicians and international guidelines 
preferring clinically driven repeat kidney biopsies.15,66 
 
8.0-Repeat Renal biopsies and Treatment decisions 
8.1 Protocol Kidney Biopsies at end of induction or maintenance treatment 
The challenge in managing LN is that even after achieving CR, patients can 
surprisingly still have active disease in their kidneys which makes protocol biopsies 
at the end of maintenance treatment useful is such cases.48 
In a prospective study of 77 patients in Saudi Arabia by Alsuwaida, only 40% of 
patients with CR had no histological evidence of active disease.48 Similarly Zickert et 
al in Sweden found that 29% of patients with CR had active lesions when protocol 
biopsies were done 8 months after induction immunosuppression.67 Recently an 
Argentinian study has also shown that LN can still be active after several years of 
immunosuppression and clinical quiescence, and that ESKD in LN can occur rapidly.57 
Therefore, remission status lacks sensitivity and specificity for differentiating renal 
activity and damage in LN.48 This makes it difficult to decide when to stop treatment 
in such cases with clinically quiescent disease after maintenance treatment without 
repeating a kidney biopsy. These active lesions may lead to rapid renal decline when 
treatment is discontinued.57,68 
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A recent multicentre study in Italy with 142 patients reported important histological 
changes at repeat biopsy and recommended use of protocol biopsies69. In this study 
the disease was more severe in both first and repeat biopsy in Class IV-G compared 
with Class III and IV-S patients and repeat renal biopsy predicted better trend of 
serum creatinine and proteinuria than the first biopsy.69,70. This important study 
strongly suggests that even in subclasses of proliferative LN important clinical and 
histological features occur which may even point towards differences in 
pathogenesis.70 
More so, it has also been observed that patients with old renal scarring may continue 
to have low-grade proteinuria despite absence of any activity at repeat biopsy 
resulting in maintenance of unnecessary immunosuppression. Alvarado et al in a 
study of 25 LN patients in Argentina illustrates this well when they found that 60% 
of those with ongoing proteinuria did not have any activity in their kidneys at the 
repeat biopsy.57 
8.2 Clinically driven repeat renal biopsies after a flare 
This mainly stems from a number of studies that have demonstrated changes in 
histological class when LN patients relapse.62,71,72 This has treatment implications 
since therapy for LN is now based on the histological class of the disease.48 In 
membranous nephritis (Class V) for example, it has been shown that as much as 35% 
can transform into proliferative classes which usually warrant treatment change.73 
Greloni et al in a retrospective study of 45 patients found re-biopsies to result in 
treatment changes in 87.3% of their cases.65 Similar findings have also been reported 
from other studies.49,59,61,62,74 
It has also been shown that the fibrosis score or degree of inflammation seen in 
repeat biopsies help in assessing prognosis, predicting flares and response to 
treatment.61,65,69,75 In a prospective study of 71 patients for example, the outcome 
of renal relapse was determined by the initial response of inflammatory and 
chronicity elements to therapy, with those with prior partial reversal of interstitial 
and glomerular scarring having a good outcome, whereas those in whom fibrotic 
lesions have continued to increase having a poor outcome.75 
23 
8.3 The Controversy 
 On the contrary, there is a scholarly view that there is no role for repeat biopsy 
either in the form of protocol biopsies or after a flare. 
 The argument here is that if one was treated for diffuse proliferative disease in the 
first biopsy for example,  the relapse is more likely to represent recurrent 
proliferative disease on second biopsy.63,76,77 Therefore, the repeat renal biopsy is 
unlikely to provide any additional data that would affect treatment in such 
patients.63,70 As much as 84% of patients with a proliferative histology in their 
reference biopsy were found by Daleboudt et al  in Netherlands to remain in a 
proliferative class at the repeat renal biopsy.63 Since the recommended treatment of 
class III and IV by guidelines is the same, treatment is unlikely to be changed in such 
cases thus making repeat biopsies unnecessary15. The small risk of bleeding and the 
cost associated with the procedure makes it imperative that the re-biopsy is 
performed when the benefit to the patient is clear.49,63   
9.0 Clinical Equipoise in Repeat Renal biopsies 
9.1-Comparative studies in Repeat Renal biopsies 
Table 6 below summarises some of the major findings from the published literature 
on studies of patients with repeat renal biopsies. The largest study to date is that of 
Lu et al from China which had 156 biopsies and had the largest histological class 
transformation (75%). There are no published reports from Africa. There is a general 
trend for CI to increase between the biopsies and lower AI at the repeat biopsy as 
shown by the table. 
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Pagni et al69 
Daleboudt et 
al63 
Wang et al64 Greloni et al65 Alvarado et al4 Lu et al78 Esdaile et al59 Bajaj et al62 
Country Italy Netherlands China Argentina Argentina China US Canada 
Sample size 142 35 44 45 25 156 42 57 
Female (%) 88.8 74.2 95 40 88 91 NR 84.2 
Publication 
year 
2013 2009 2012 2014 2014 2011 1993 2000 
Study 
design 










4.9 ± 4.9 4.1 ± 3.6 NR 3.4(4.4) * 6 NR 2.1(1.8-2.5) ** 4.2yrs 
AI-1/AI-2 4.5 / 3.3 6.18 / 5.27 5.8 / 4.7 NR 8.9/4.3/0.96 6.8 7/2 5.09/3.96 


















































NR 77.5 34 87.3 64 NR NR 77 
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9.2 Gaps in Literature 
• No studies in South Africa and the whole of Africa looking at repeat biopsies 
in patients with lupus nephritis. This is an important area to study given that 
LN is not rare  in Africa9 and in fact it is probably more aggressive and thus 
limiting the generalisability of data from other parts of the world. There is 
strong evidence for the genetic heterogeneity of SLE and reported 
differences in severity in different population groups making it imperative to 
have local data to guide clinicians. (Appendix 7) 
• Evidence available is from very small studies which are mainly retrospective 
in nature looking at the utility of re-biopsies hence larger prospective trials, 
using protocol biopsies, are needed to investigate more deeply the 
relationship between histology and clinical data in re-biopsies. 
 
9.3 - Rationale of the present study 
Due to paucity and absence of quality evidence for re-biopsy of patients with LN, the 
KDIGO recommendation is to either repeat kidney biopsies or change to an 
alternative recommended initial therapy in patients with rising creatinine or 
proteinuria during the first 3 months of treatment.15 KDIGO also recommends that if 
CR has not been achieved after 12 months of maintenance therapy, to consider 
performing a repeat kidney biopsy before change in therapy.15 
 At Groote Schuur Hospital (GSH), we do not routinely perform kidney biopsies after 
starting immunosuppressive treatment (Protocol biopsies). Rather, patients are 
routinely monitored and followed up using clinical measures such as serum 
creatinine, urine protein excretion, and urine microscopy. Persistent abnormalities 
of these measures are utilized for deciding timing of repeat renal biopsies in patients 
with LN. We therefore repeat renal biopsies in our patients at GSH if there is evidence 
of worsening disease or refractory to treatment, evidence of relapse (to show 
transformation or progression in histological class or change in activity and chronicity 
scores) and to demonstrate other pathologies.10 This is in line with international best 
practice.61,62 It therefore remains unclear whether repeat biopsies result in clinically 
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meaningful histological changes and thus significant treatment changes due to 
unavailable local  data.  
10.0 Study Objectives 
10.1 Main Objective 
To evaluate the clinical relevance of repeat renal biopsy in patient with LN as 
practised in the renal unit at GSH. 
10.2 Specific objectives 
1.To compare the histological class before and after the biopsy.  
2.To determine the proportion of patients whose treatment was altered after the 
repeat biopsy. 
3.To compare the activity and chronicity indices between the repeat and reference 
biopsy. 
4 To compare clinical and laboratory features (proteinuria, serum creatinine) 
before and after biopsy. 
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Background: Repeat renal biopsies in patients with lupus nephritis (LN) are usually 
done to guide treatment or to establish disease chronicity. Their value is not clear 
from available literature. There is also no available data in Africa to guide clinicians. 
Methods: This was a retrospective study of patients undergoing a repeat renal 
biopsy between January 2003 and December 2014 from a single centre in Cape 
Town, South Africa. Relevant demographic, clinical and histological records of 
patients with repeat renal biopsies were documented. Comparison of data from 1st 
and 2nd renal biopsy was performed.  
Results: 44 patients had at least 2 biopsies done during the study period. Most 
patients were females (81.8%). The mean biopsy interval was 2.8± 1.8 (range 0.38 – 
9.4) years. Proteinuria was the main indication for the repeat biopsy (36.1%). The 
glomerular filtration rate and proteinuria worsened between the two biopsies 
(p=0.001 and 0.019) respectively suggesting disease progression. Most patients 
(65.4%) with a non-proliferative class of LN at first biopsy progressed into a 
proliferative class whereas patients with initial proliferative LN at first biopsy (77.8%) 
remained as proliferative at repeat biopsy. Treatment was changed in 85% of 
patients at second biopsy.  
Conclusion: Repeat renal biopsies in patients with LN presents a useful means of 
assessing disease progression and provides guidance regarding modification of 
treatment. More studies are however required to evaluate the value of repeat 
biopsies and perhaps the need for protocol renal biopsies in patients with LN.   
Keywords 








Patients with lupus nephritis (LN) may experience frequent flares over the course of 
their disease.1 Clinical and laboratory features are often not sufficient to guide the 
treatment of these patients hence the need for repeat renal biopsies. 2-4 As there is 
no consensus about repeat renal biopsies in patients with LN, they are either 
performed as protocol biopsies at the end of induction or maintenance treatment or 
only when a flare is suspected, but this is centre specific. 5, 6  
LN patients with chronic renal scarring may continue to have low-grade proteinuria 
even without any disease activity in their kidneys resulting in unnecessary 
immunosuppression with potential for complications. 7 Alvarado et al in a study of 
25 LN patients in Argentina illustrates this well when they found that 60% of those 
with ongoing proteinuria did not have any activity in their kidneys at the repeat 
biopsy.7 Thus, clinically quiescent LN during ongoing maintenance treatment 
presents a challenge regarding timing of reduction or discontinuation of 
immunosuppression without repeating a renal biopsy as there may be histologically 
active disease. 7, 8 One of the important reason for repeat biopsies in patients with 
LN is to identify significant class transformations requiring change of therapy.2, 9-15 
However, there are questions regarding the value of these repeat biopsies if the first 
biopsy showed proliferative LN given that the same is likely to be seen on repeat 
biopsy.15, 16 In one study, 84% of patients with  proliferative histology in their 
reference biopsy remained in a proliferative class of LN at repeat biopsy 17. Currently, 
there is insufficient evidence for major guidelines to make strong recommendations 
on repeat renal biopsy. 18 At our centre in Cape Town, repeat renal biopsies are 
performed in patients with LN to assess disease activity during a flare or to determine 
degree of chronic changes, both criteria driven by the need to understand if 
treatment change will be required.   
The utility of a repeat renal biopsy in patients with biopsy proven LN has not been 
thoroughly investigated in Africa. The aim of this study is therefore to assess the 





This study was approved by the Human Research Ethics Committee of the University 
of Cape Town (HREC Ref 732/2014) and was designed as a retrospective analysis of 
repeat renal biopsies performed for patients known with LN from 1st January 2003 
to 31st December 2014. We identified eligible patients through our local renal biopsy 
database.  Patients who have had only one renal biopsy, transplant biopsies and all 
other cases of non-lupus biopsies were excluded. Although a few patients had more 
than 2 biopsies performed during the period of assessment, our focus was to 
compare the clinical, biochemical, histological and treatment features observed 
between 1st and 2nd biopsies.  Paper and electronic records were searched to obtain 
relevant demographic, clinical, histological and treatment information on all patients 
who were included. The indication for repeat renal biopsy was categorized as: (i) 
active urinary sediment, (ii) elevated serum creatinine, (iii) elevated serum 
creatinine with a urinary abnormality (active sediment, presence of red blood cells 
or casts, proteinuria), and (iv) elevated proteinuria.A second Pathologist different 
from the one who reported the initial biopsies again reviewed all histological reports 
and entered the ISN/RPS final class .19 Activity and chronicity scores for each patient 
at the time of first and second biopsies were assessed and recorded using standard 
criteria.20  
The average time between 1st and 2nd   biopsies was calculated and recorded. Clinical 
features, histological findings and differences in frequency of LN class between 
biopsies were recorded. The estimated Glomerular filtration rate (eGFR) was 
calculated using the Modification of Diet in Renal Disease (MDRD) equation.21 
Treatment received for induction and maintenance therapies at 1st and 2nd renal 
biopsies were also documented. Changes to treatment that occurred due to the 
histologic findings of the 2nd renal biopsy was recorded as: (i) treatment escalation – 
if there was need to increase dose of corticosteroids or other alkylating agents or 
introduce a new immunosuppression; (ii) treatment reduction – if there was need to 
stop or reduce the dose of ongoing immunosuppression; and (iii) no change to 
treatment if there was no change in dose or type of immunosuppression given after 




The data was analysed using SPSS Version 23.0 for Windows (SPSS Chicago IL). The 
results were presented as percentages or as mean ± SD. The students t-test (for 
continuous variables) and the chi-square test (for categorical variables) were used to 
test for differences between variables at the 1st and 2nd biopsies. P-values less than 
0.05 was considered statistically significant. 
Results 
A total of 2581 native renal biopsies were performed during the study period. Of 
these, 369 (14.3%) were in patients with LN of which 44 patients (11.9%) had at least 
one repeat biopsy. The baseline and demographic characteristics of the patients at 
biopsy 1 and 2 are shown in Table 1. The average age at first biopsy was 25.7 ±10.3 
years and 28.4 ±10.2 years at 2nd biopsy with mean biopsy interval being 2.8±1.8 
years. Most patients were females (81. 8%) and there was a predominance of 
patients of mixed ancestry (75%) while black Africans and white patients made up 
22.7% and 1.8% respectively. 
Elevated proteinuria was the main indication for renal biopsy at 1st and 2nd biopsy 
(48.7% vs 36.1%; p=0.489) respectively. A significantly increased number of patients 
had a repeat biopsy due to elevated serum creatinine, compared to the first biopsy 
(5.1% vs 13.9%; p=0.016). Similarly, there was an increase in the proportion of 
patients who had a re-biopsy due to elevated serum creatinine with abnormal urine 
sediment at second biopsy than at first biopsy (12.8% vs 27.8%, p=0.895) (Table 1).  
There was a significant reduction in the proportion of patients with positive double 
stranded DNA at 2nd biopsy (69.9% vs 63.6%; p=0.022). There was also significant 
worsening of eGFR between 1st and 2nd biopsies (88.9±49.2ml/min vs 
54.7±59.0ml/min; p=0.001) as well as significant worsening of proteinuria (3.0 
g/24hrs±3.0 vs 5.0 g/24hrs±4.0, p=0.019) (Figure 1). 
The mean number of glomeruli obtained at both biopsies were similar (14.1± 8.7 and 
14.3 ± 7.5; p=0.890) and there were no significant differences in the average number 
of cellular crescents (p=0.195), number of fibrous crescents (p=0.173) and 
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percentage of interstitial fibrosis (p=0.309) seen. However, there were significantly 
more patients with crescents at the second biopsy (p=0.005). The mean activity index 
(3.9±4.4 vs 7.0±5.7; p=0.005), chronicity index (1.0±1.5 vs 3.5±2.7; p=0.000) and 
number of sclerosed glomeruli (0.5±1.2 vs 4.3±7.8; p=0.004) were significantly raised 
at the repeat biopsy time point, respectively. In addition, we frequently observed 
transformation in histological class between initial and follow-up biopsies; 40.9% had 
proliferative LN at 1st biopsy compared to 70.4% at 2nd biopsy (Figure 2). At 2nd biopsy, 
class transformation was 100% for patients with class I LN at 1st biopsy, 80% for those 
with class II LN, and 86% for those with class V LN, respectively (Table 2). Most of the 
transformation of class at 2nd biopsy was to class IV. Majority of patients with 
proliferative LN at 1st biopsy (77.8%) remained in one of the proliferative classes 
whereas 65.4% with an initial non-proliferative LN class transformed into a 
proliferative class at 2nd biopsy. 
Treatment given for induction and maintenance therapies as well as other adjunctive 
therapies given to patients after the 1st and 2nd   biopsies are shown in (Table 3). The 
repeat biopsy resulted in immunosuppressive treatment escalation in 72.5%, 
reduction in 12.5% and no changes to treatment in 15.0%. Hence, there was an 
overall treatment change in 85.0% as a result of the second biopsy. (Table 3. 
 
Discussion 
This study shows that there is a significant class transformation in patients with LN 
undergoing a repeat renal biopsy at our center. The observed change in LN class 
between the initial and follow-up biopsies led to significant change in treatment 
following repeat biopsy. This therefore points to the need for protocols for repeat 
biopsies in our setting given the implications for disease outcome. One large 
International cohort study of repeat biopsies in patients with LN also found 
significant class switch at repeat biopsy and concluded that a repeat biopsy strategy 
could provide additional information on long-term renal outcomes.22 The same study 
also suggested that a strategy of protocol biopsies could be useful in clinical trials to 
better understand the therapeutic response and the natural history of LN.22  
39 
Although the KDIGO guideline does not specifically provide information regarding 
the timing of a repeat biopsy in patients with LN, repeat biopsies have often been 
performed during a disease flare 10, 12, 13, 17 or as protocol biopsies at the end of 
induction therapy7, 23-25 or at 1 – 2 years to assess the efficacy of maintenance 
therapy.6, 15, 26, 27 In a study, comparing the histologic and clinical responses of 
proliferative LN to standard-of-care induction therapies, Malvar et al found that 7 
patients showed persistent cellular crescents and sub endothelial immune deposits 
and/or glomerular capillary necrosis at repeat biopsy and that 2 of these patients 
had achieved complete clinical renal response, one patient had a partial renal 
response and four had no renal response.25 The patients were treated for another 6 
months of MMF (3 g/day), before being placed on maintenance 
immunosuppression. They concluded that early clinical and histologic outcomes are 
discordant in proliferative LN, and neither correlates with long-term renal 
outcome.25 However, use of protocol biopsies, rather than biopsies performed only 
during a clinical disease flare, may be more likely to provide better evidence for 
disease progression, patient outcome and need for early treatment change. More 
data is still needed from prospective studies and clinical trials to define the role of 
protocol biopsies in understanding disease pathogenesis and outcomes.  
Our study also showed that most patients who on initial biopsy had a proliferative 
LN, especially patients with class IV LN, often remained in the same class at follow 
up biopsy. This is in agreement with Daleboudt et al who reported that 84% of 
patients in their study with proliferative LN at 1st biopsy continued to have 
proliferative disease at repeat biopsy.17  This finding questions the value of repeating 
a kidney biopsy in such patients if the initial biopsy was of a proliferative type. On 
the other hand  some may justify the need for repeat biopsies in patients with initial 
proliferative LN given that it often leads to change in current treatment12. However, 
the change of treatment as reported in this study is that of change from ongoing 
maintenance treatment (minimal immunosuppression) to a new induction phase 
treatment (increased dose or new immunosuppression) Table 3. As shown in the 
table the proportion of patients getting induction treatment after second biopsy 
appear fewer than at 1st biopsy because the change in treatment is from 
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maintenance treatment before 2nd biopsy not comparison between induction 
therapies at the 2 biopsies. Thus, whether a repeat biopsy in patients with initial 
proliferative LN is only needed to guide therapeutic changes will remain a matter of 
debate. This is because in many patients, treatment escalation would still have 
occurred from a clinical perspective due to an ongoing flare.  
Change in chronicity score at repeat biopsy may remain a strong reason to advocate 
for repeat biopsy in patients with LN and should be reported in all biopsies of 
patients with LN.28 In the current study, there was a significant increase in both 
activity and chronicity indices between biopsies (Figure 3) translating to significantly 
reduced eGFR and increased 24-hour proteinuria between biopsies (Figure 1). 
Several other studies have shown significant increases in chronicity scores at repeat 
biopsy even after initial successful treatment.27, 29 Bao et al reported a significantly 
ameliorated activity index (p<0.0001) at repeat biopsy whereas chronicity index had 
significantly increased (p=0.028) in patients at complete remission after induction 
therapy in a study that investigated the value of multi-targeted therapy in patients 
with proliferative LN.29  They found no difference in AI (p=0.346) and significant 
increase in chronicity index (p=0.032) for patients who did not achieve complete 
remission after induction therapy.29 The average biopsy interval in many studies that 
report increased chronicity score at repeat biopsy is often between 2.1 to 6 years 
(Table 4).7, 9, 12, 17, 22, 24, 30 The average biopsy interval from our center was 2.8±1.8 
years which could be the reason for the significantly increased chronicity score 
obtained at repeat biopsy. 
There are some limitations we encountered in conducting this research, for instance, 
although the pathologists at our center use the ISN/RPS classification for LN, 
subclasses that reports segmental or global lesions in the biopsy are not routinely 
reported. Such information may have helped us to understand how those patients 
with a predominantly proliferative class of disease change classes (e.g. from IV[S] to 
IV[G]) even though they still remained within the proliferative type of LN. Other 
limitations are the retrospective design of the study and the low sample size 
available for analysis. However, the strength of this study is that it has been reported 
from a developing country setting where renal biopsies are usually not available in 
41 
 
the evaluation of patients and therefore may provide assurance for the clinical 
treatment of patients with suspected proliferative disease in the absence of facilities 
to perform a kidney biopsy. We however urge that a biopsy be considered to guide 
therapy in such patients where possible. 
Conclusion: 
Repeat renal biopsies in patients with LN presents a useful means of assessing 
disease progression and provides guidance regarding modification of treatment. 
More studies are however required to evaluate the value of repeat biopsies and 
perhaps the need for protocol renal biopsies in patients with LN.  
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Figure 1: Differences in estimated glomerular filtration rate and protein excretion 
between1st and 2nd biopsy. 
1(a): shows change in estimated GFR between first and second renal biopsy; eGFR-
BX1 – estimated glomerular filtration rate at first biopsy; eGFR-BX-2 – estimated 
glomerular filtration rate at 2ND biopsy; 1(b): shows changes in urine protein 
creatinine ratio between biopsy 1 and biopsy 2; UPCR – urine protein-to-creatinine 
ratio 
Figure 2: Histological class switches between first and second biopsy 
Proliferative classes: class 3,4,3+5 and 4+5 
Non-Proliferative classes: class 1,2,5 and 6 
Figure 3: Shows changes in Activity and Chronicity index between biopsy 1 and 
biopsy 2. 
3(a): Shows changes in Activity index between biopsy 1 and 2; 3(b): Shows changes 
in Chronicity index between biopsy 1 and 2 
 
Figure 1                                                          n=44     
Figure 1: Differences in estimated glomerular filtration rate and protein excretion 
between reference and 2nd biopsy.1(a): shows change in estimated GFR between 
first and second renal biopsy; eGFR-BX1 – estimated glomerular filtration rate at 
first biopsy; eGFR-BX-2 – estimated glomerular filtration rate at 2ND biopsy; 1(b): 
shows changes in urine protein creatinine ratio between biopsy 1 and biopsy 2; 
UPCR – urine protein-to-creatinine ratio 
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Figure 2  n=44 
Figure 2: Histological class switches between first and repeat biopsy 
Proliferative classes: class 3,4,3+5 and 4+5 
Non-Proliferative classes: class 1,2,5 and 6 
Figure 3                                                              n=44 
Figure 3: Shows changes in Activity and Chronicity index between biopsy 1 and 
biopsy 2.3(a): Shows changes in Activity index between biopsy 1 and 2; 3(b): Shows 

















Demographics    
Age (Range) (Years) 25.7 ±10.3  28.4±10.2  <0.0001 
Gender (Female) (%) 81.8 81.8  
Race (%)-black 22.7 22.7  
-coloured 75.0 75.0  
-white 1.8 1.8  
Biopsy interval (years) 2.8±1.8  
Biopsy indications (%)    
- Active urine 33.3 22.2 0.777 
- Elevated Scr* 5.1 13.9 0.016 
-Elevated Scr + urine abnormality 12.8 27.8 0.895 
- Elevated proteinuria 48.7 36.1 0.489 
Clinical and Laboratory variable    
SBP(mmHg) 128.2±26.7 141.0±27.5 0.015 
DBP(mmHg) 77.0±19.0 88.0±18.7 0.006 
eGFR(ml/min) 88.9±49.2 54.7±59.0 0.001 
UPCR(mg/mmol) 0.3±0.3 0.5±0.4 0.019 
Albumin(g/l) 27.9±8.5 27.5±6.7 0.799 
C3 0.46±0.40 0.62±0.35 
0.742 
Low C3 (%) 52.3 54.5 
C4 0.13±0.11 0.19±0.16 
0.194 
Low C4 (%) 25.0 20.5 
Anti dsDNA level 507.9±323.9 306.2±282.1 
0.022 
Positive ds-DNA (%) 69.9 63.6 
Histology    
Number of glomeruli 14.1±8.7 14.3±7.5 0.890 
Interstitial fibrosis present (%) 30.8 46.2 0.309 
Activity index 3.9±4.4 7.0±5.7 0.005 
Chronicity index 1.0±1.5 3.5±2.7 0.000 
Number of patients with cellular 
crescents (%) 
8.0(18.2) 18.0(40.9) 0.005 
Average number of cellular  
crescents per biopsy 
1.2±3.4 2.0±3.4 0.195 
Number of patients with sclerosed 
gloms (%) 
10.0(22.7) 23.0(52.3) 0.724 
Average number sclerosed gloms 
per biopsy 
0.5±1.2 4.3±7.8 0.004 
Number of patients with fibrous 
crescents (%) 
3.0(6.8) 4.0(9.1) 0.254 
Average number of fibrous 
crescents per biopsy 
0.1±0.3 0.5±1.9 0.173 
Number of patients with 
necrotizing lesions (%) 
9.0(20.5) 14.0(31.8) 1.000 
Average number of necrotizing 
lesions per biopsy 
0.2±0.4 0.9±1.9 0.025 
 
Normal Ranges C3: 0.90 - 1.8   C4: 0.10 - 0.40  




Table 2: Histological Changes between First and Second Biopsy 
First Biopsy 
(n=44) 

















I(n=2) 0 0 2 0 0 0 0 100 
II(n=10) 2 1 3 1 0 2 1 80 
III(n=7) 1 2 2 1 0 1 0 71 
IV(n=8) 0 1 6 0 0 0 1 25 
V(n=14) 0 0 4 2 2 3 3 86 
V+IV(n=3) 0 0 2 1 0 0 0 100 
 
 




Biopsy 1 (%) 
n=44 
 
Biopsy 2 (%) 
n=44 
 
General    
Chloroquine 64.1 45.9 
ACEI 88.9 84.2 
Induction   
Pulse Methyl Prednisolone 36.8 47.4 
Cyclophophamide 62.5 59.0 
Mycophenolate mofetil 7.7 5.3.0 
Maintenance   
Prednisolone 97.4 89.7 
Azathioprine 50.0 43.6 
Mycophenolate mofetil 20.5 15.9 
Cyclosporine 2.6 2.3 
   
Treatment Escalation 72.5 
Treatment Reduction 12.5 
No Change 15.0 
Overall Treatment change 85.0 
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Table 4: Features from selected studies of repeat renal biopsies in patients with lupus nephritis from various centres 
*Median Inter quartile range    **Interquartile range     # Information missing. 
NR: Not reported.    AI: Activity Index.     CI= Chronicity Inde
Pagni et al22 Daleboudt et al17 Wang et al9 Greloni et al12 Alvarado et al7 Lu et al30 Esdaile et al15 Bajaj et al10 
Kajawo et al 
Current study 
Country Italy Netherlands China Argentina Argentina China US Canada South Africa 
Sample size 142 35 44 45 25 156 42 57 44 
Female (%) 88.8 74.2 95 40 88 91 NR 84.2 81.8 
Publication year 2013 2009 2012 2014 2014 2011 1993 2000 2016 
Study design Retrospective Retrospective Retrospective Retrospective Prospective Retrospective Prospective Retrospective Retrospective 
Study duration (type) 
37yrs (multi-
centre) 
NR(single) 16yrs(single) 8.7yrs(single) 6yrs (single) 20yrs(single) 17yrs(single) 24yrs(Single) 12yrs(single) 
Biopsy interval in years (SD) 4.9 ± 4.9 4.1 ± 3.6 NR 3.4(4.4) * 6 NR 2.1(1.8-2.5)** 4.2yrs 2.8±1.8 
AI-1/AI-2 4.5 / 3.3 6.18 / 5.27 5.8 / 4.7 NR 8.9/4.3/0.96 6.8 7/2 5.09/3.96 3.92/7.03 
CI-1 / CI-2 1.5 / 3.6 2.6 / 4.2 1.8/3.4 2.9/6.6 2.8/4.2/4.3 2.6 2/2 1.30/3.37 0.97/3.53 
Change in chronicity score +2.1 +1.6 +1.6 NR +1.5 NR 0 +2.07 +2.56 
 Proliferative class at biopsy 1 
and 2(%) 
70.3/70.4 87.8/93.9 NR 60/66.7 NR 71.7/59.4 83.3/50 58/44 40.9/70.4 






60 54.3 75 77.8 
Non-Proliferative to Proliferative 
switch (%) 
42.9 
83.3 NR 58.3 NR 58 28.6 22.2 65.4 
Overall Pathological transition 
(%) 
40.8 55.7 64 54.9 NR 75 46 40.4 72.7 
Proteinuria biopsy g/24h 1/2 (%) 3.5/3.1 NR NR NR 3.3/1.13/0.32 3.28/# 0.99/0.50 2.48/1.35 3/5 









Gender Race            




































               





HB Bx-1 WBC Bx-
1 


















               

































































































































Appendix 2: Ethics Approval Letter 
52 
Appendix 3: Acceptance of Abstract for Poster Presentation at South African Renal 
Congress 
53 




Appendix 5: Acceptance for Publication in Lupus 
Decision Letter (LUP-16-608.R1) 
From: editorial@lupusjournal.co.uk 
To: skajawo@gmail.com, skajawo@yahoo.co.uk 
CC:  
Subject: Lupus - Decision on Manuscript ID LUP-16-608.R1 
Body: 01-Feb-2017  
 
Dear Dr. Kajawo:  
 
Thank you very much for revising your  manuscript entitled 
"Clinico-pathological features of repeat renal biopsies in patients 
with lupus nephritis at Groote Schuur Hospital, Cape Town.". I 
am very pleased to let you know that this has now been accepted 
for publication in Lupus and you should receive proofs from the 
publishers within the next few weeks.  
 
You will shortly receive a second email requesting you submit a 
contributor agreement online without which we cannot 
commence with publication.  
 
If you would like your article to be freely available online 
immediately upon publication (as some funding bodies now 
require), you can opt for it to be published under the SAGE 
Choice Scheme on payment of a publication fee. Please simply 
follow the link to the Contributor Agreement form in the next 
email and you will be able to access instructions and further 
information about this option within the online form.  
 
Thank you very much for your contribution to Lupus.  We look 
forward to your continued support.  
 
With best regards.  
 
Yours sincerely,  
 
Maria Laura Bertolaccini  
Managing Editor  







Appendix 6: Instructions to Authors Lupus Journal-SAGE 
The manuscript has been accepted by  LUPUS for publication  
“Manuscript Submission Guidelines 
Pre-submission: helping readers find your article 
Before you submit your manuscript, go back and review your title, keywords and 
abstract. These elements are key to ensuring that readers will be able to find your 
article online through online search engines such as Google. More information and 
guidance on how best to title your article, write your abstract and select your 
keywords can be found here: How to Help Readers Find Your Article Online. 
One simple thing you can do to improve your article’s visibility and ensure proper 
indexing and cross-linking is to provide full names for all authors. Please refer 
to our guidelines for author names, prepared in consultation with Google Scholar, 
for more information. 
Submitting your article 
Each SAGE journal has its own editorial office and its own instructions for authors. 
To submit your article, visit your chosen journal’s homepage and click on the 
manuscript submission guidelines link. View the list of all our journals here. 
Our general guidance for authors can be found below. Please be sure to read your 
chosen journal’s guidelines as each journal will have its own specific requirements. 
Please direct queries on the submission process to the journal’s editorial office; 
details can be found within each journal’s submission guidelines. Other queries 
may be sent to authorqueries@sagepub.co.uk 
SAGE is a member of the Committee on Publication Ethics (COPE) and follows their 
best practice guidelines. 
For authors submitting to medical journals, SAGE recommends that authors follow 
the Uniform Requirements for Manuscripts Submitted to Biomedical Journals 
formulated by the International Committee of Medical Journal Editors (ICMJE). 
Editorial policies 
Peer review policy 
Please see the submission guidelines of the journal you wish to submit to. View the 
complete list of SAGE Journals.  
Please note that as part of the submission process you may be asked to provide the 
names of a number of peers who could be called upon to review your manuscript. 
Recommended reviewers should be experts in their fields and should be able to 
provide an objective assessment of the manuscript. Please be aware of any 
conflicts of interest when recommending reviewers. Examples of conflicts of 
interest include (but are not limited to) the below:  
57 
 
• The reviewer should have no prior knowledge of your submission 
• The reviewer should not have recently collaborated with any of the authors 
• Reviewer nominees from the same institution as any of the authors are not 
permitted 
Please note that the journal’s editors are not obliged to invite any 
recommended/opposed reviewers to assess your manuscript. 
Authorship 
For authors submitting to technical or medical journals, papers should only be 
submitted for consideration once consent is given by all contributing authors. 
Those submitting papers should carefully check that all those whose work 
contributed to the paper are acknowledged as contributing authors.  
The list of authors should include all those who can legitimately claim authorship. 
This is all those who: 
1. Made a substantial contribution to the concept and design, acquisition of 
data or analysis and interpretation of data, 
2. Drafted the article or revised it critically for important intellectual content, 
3. Approved the version to be published. 
Authors should meet the conditions of all of the points above. Each author should 
have participated sufficiently in the work to take public responsibility for 
appropriate portions of the content. 
When a large, multicentre group has conducted the work, the group should identify 
the individuals who accept direct responsibility for the manuscript. These 
individuals should fully meet the criteria for authorship. 
Acquisition of funding, collection of data, or general supervision of the research 
group alone does not constitute authorship, although all contributors who do not 
meet the criteria for authorship should be listed in the Acknowledgments section. 
Please refer to the International Committee of Medical Journal Editors (ICMJE) 
authorship guidelines for more information on authorship. 
For authors submitting to social science or humanities journals, all parties who 
have made a substantive contribution to the article should be listed as authors. 
Principal authorship, authorship order, and other publication credits should be 
based on the relative scientific or professional contributions of the individuals 
involved, regardless of their status. A student is usually listed as principal author on 
any multiple-authored publication that substantially derives from the student’s 
dissertation or thesis. 
General guidance for authors submitting to medical journals (please view the 
journal’s submission guidelines for specific requirements) 
58 
 
Research ethics and patient consent 
Medical research involving human subjects must be conducted according to the 
World Medical Association Declaration of Helsinki 
Submitted manuscripts should conform to the ICMJE Recommendations for the 
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, 
and all papers reporting animal and/or human studies must state in the methods 
section that the relevant Ethics Committee or Institutional Review Board provided 
(or waived) approval. Please ensure that you have provided the full name and 
institution of the review committee, in addition to the approval number. 
For research articles, authors are also required to state in the methods section 
whether participants provided informed consent and whether the consent was 
written or verbal. 
Information on informed consent to report individual cases or case series should be 
included in the manuscript text. A statement is required regarding whether written 
informed consent for patient information and images to be published was provided 
by the patient(s) or a legally authorized representative. 
Please also refer to the ICMJE Recommendations for the Protection of Research 
Participants 
All research involving animals submitted for publication must be approved by an 
ethics committee with oversight of the facility in which the studies were 
conducted. 
Clinical trials 
Many SAGE journals conform to the ICMJE requirement that clinical trials are 
registered in a WHO-approved public trials registry at or before the time of first 
patient enrolment as a condition of consideration for publication. The trial registry 
name and URL, and registration number must be included at the end of the 
abstract. 
Further to the above, other SAGE journals may consider retrospectively registered 
trials if the justification for late registration is acceptable, consistent with the 
AllTrials campaign. The trial registry name and URL, and registration number must 
be included at the end of the abstract. 
Reporting guidelines 
The relevant EQUATOR Network reporting guidelines should be followed 
depending on the type of study. For example, all randomized controlled trials 
submitted for publication should include a completed Consolidated Standards of 
Reporting Trials (CONSORT) flow chart as a cited figure, and a completed CONSORT 
checklist as a supplementary file. 






SAGE is committed to upholding the integrity of the academic record. We 
encourage authors to refer to the Committee on Publication Ethics’ International 
Standards for Authors and view the Publication Ethics page on the SAGE Author 
Gateway 
Plagiarism 
SAGE takes issues of copyright infringement, plagiarism or other breaches of best 
practice in publication very seriously. We seek to protect the rights of our authors 
and we always investigate claims of plagiarism or misuse of published articles. 
Equally, we seek to protect the reputation of the journal against malpractice. 
Submitted articles may be checked with duplication-checking software. Where an 
article, for example, is found to have plagiarised other work or included third-party 
copyright material without permission or with insufficient acknowledgement, or 
where the authorship of the article is contested, we reserve the right to take action 
including, but not limited to: publishing an erratum or corrigendum (correction); 
retracting the article; taking up the matter with the head of department or dean of 
the author's institution and/or relevant academic bodies or societies; or taking 
appropriate legal action. 
Previous distribution and/or publication 
The author should disclose any prior distribution and/or publication of any portion 
of the material to the Editor for the Editor’s consideration and ensure that 
appropriate attribution to the prior distribution and/or publication of the material 
is included. For more information, visit our Prior Publication page on the SAGE 
Journal Author Gateway. 
Contributor’s publishing agreement 
Before publication, SAGE requires the author as the rights holder to sign a Journal 
Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing 
Agreement for traditional subscription journals is an exclusive licence agreement 
which means that the author retains copyright in the work but grants SAGE the sole 
and exclusive right and licence to publish for the full legal term of copyright. 
Exceptions may exist where an assignment of copyright is required or preferred by 
a proprietor other than SAGE. In this case copyright in the work will be assigned 
from the author to the society. This licence enables authors to make articles open 
access by archiving their article at no charge via the green open access 
archiving route. Authors who have published in a subscription journal can do this 
by depositing the version of the article accepted for publication (version 2) in their 
own institution's repository.  
For more information please visit our Frequently Asked Questions on the SAGE 
Journal Author Gateway. 
60 
 
SAGE Choice - publishing open access in a subscription journal 
The SAGE Choice program offers authors the option to make their articles freely 
available upon publication in most subscription-based SAGE journals. It also 
enables authors to comply with funding body requirements, where publishing 
research papers open access is a stipulation of funding, while still publishing their 
article in the subscription journal of their choice. The licence used is the same open 
access contributor's publishing agreement.  
Open Access contributor's publishing agreement 
SAGE open access journals all publish articles under Creative Commons licences. 
The standard licence is Creative Commons by Attribution Non-Commercial (CC BY-
NC), which allows others to re-use the work without permission as long as the work 
is properly referenced and the use is non-commercial. Alternative licence 
arrangements are available, for example, to meet particular funder mandates, 
made at the author's request. For more information, you are advised to visit SAGE's 
open access licences page.  
Permissions 
Authors are responsible for obtaining permission from copyright holders for 
reproducing any illustrations, tables, figures or lengthy quotations previously 
published elsewhere. For further information including guidance on fair dealing for 
criticism and review, please visit our Frequently Asked Questions on the SAGE 
Journal Author Gateway 
Preparing your manuscript 
Formatting your article 
When formatting your references, please ensure you check the reference style 
followed by your chosen journal. Here are quick links to the SAGE Harvard 
reference style, the SAGE Vancouver reference style and the APA reference style. 
Other styles available for certain journals are: ACS Style Guide, AMA Manual of 
Style, ASA Style Guide, Chicago Manual of Style and CSE Manual for Authors, 
Editors, and Societies.  Please refer to your journals’ manuscript submission 
guidelines to confirm which reference style it conforms to. 
Equations should to be submitted using Office Math ML and Math type. 
Word template and guidelines 
Our tailored Word template and guidelines will help you format and structure your 
article, with useful general advice and Word tips. 
(La)TeX template and guidelines 
We welcome submissions of (La)TeX files. Please download the SAGE LaTeX 
template, which contains comprehensive guidelines. 
61 
 
If you have used any .bib files when creating your article, please include these with 
your submission so that we can generate the reference list and citations in the 
journal-specific style. 
If you need any help with your submission, please email 
SageTeXsupport@sagepub.com 
Artwork guidelines 
Illustrations, pictures and graphs, should be supplied with the highest quality and in 
an electronic format that helps us to publish your article in the best way possible. 
Please follow the guidelines below to enable us to prepare your artwork for the 
printed issue as well as the online version. 
• Format: TIFF, JPEG: Common format for pictures (containing no text or 
graphs).  
EPS: Preferred format for graphs and line art (retains quality when 
enlarging/zooming in). 
• Placement: Figures/charts and tables created in MS Word should be 
included in the main text rather than at the end of the document. 
Figures and other files created outside Word (i.e. Excel, PowerPoint, JPG, 
TIFF, EPS, and PDF) should be submitted separately. Please add a 
placeholder note in the running text (i.e. “[insert Figure 1.]") 
• Resolution: Rasterized based files (i.e. with .tiff or .jpeg extension) require a 
resolution of at least 300 dpi (dots per inch). Line art should be supplied 
with a minimum resolution of 800 dpi. 
• Colour: Please note that images supplied in colour will be published in 
colour online and black and white in print (unless otherwise arranged). 
Therefore, it is important that you supply images that are comprehensible 
in black and white as well (i.e. by using colour with a distinctive pattern or 
dotted lines). The captions should reflect this by not using words indicating 
colour. 
• Dimension: Check that the artworks supplied match or exceed the 
dimensions of the journal. Images cannot be scaled up after origination 
• Fonts: The lettering used in the artwork should not vary too much in size 
and type (usually sans serif font as a default). 
English language editing services 
Authors seeking assistance with English language editing, translation, or figure and 
manuscript formatting to fit the journal’s specifications should consider using SAGE 
Language Services. Visit SAGE Language Services on our Journal Author Gateway for 
further information. 
Submitting your manuscript 
62 
 
How to submit your manuscript 
Many SAGE journals are hosted on SAGE Track, a web based online submission and 
peer review system powered by ScholarOne™ Manuscripts. Please see the 
submission guidelines of the journal you wish to submit to find out its preferred 
submission method. 
IMPORTANT: If submitting through SAGE Track, please check whether you already 
have an account in the system before trying to create a new one. If you have 
reviewed or authored for the journal in the past year it is likely that you will have 
had an account created.  For further guidance on submitting your manuscript 
online please visit ScholarOne Online Help. 
Title, keywords and abstracts 
You will be asked to supply a title, short title, an abstract and keywords to 
accompany your article. The title, keywords and abstract are key to ensuring 
readers find your article online through online search engines such as Google. 
Please refer to the information and guidance on how best to title your article, write 
your abstract and select your keywords by visiting the SAGE Journal Author 
Gateway for guidelines on How to Help Readers Find Your Article Online 
Video abstracts 
Some journals accept video abstracts (please check the submission guidelines of 
your chosen journal). Read our guidelines on how to produce a video abstract 
On acceptance and publication 
SAGE Production 
Your SAGE Production Editor will keep you informed as to your article’s progress 
throughout the production process. Proofs will be sent by PDF to the 
corresponding author and should be returned promptly. 
Access to your published article 
SAGE provides authors with online access to their final article. 
Online First publication 
Many SAGE journals offer Online First. Online First allows final revision articles 
(completed articles in queue for assignment to an upcoming issue) to be published 
online prior to their inclusion in a final journal issue which significantly reduces the 
lead time between submission and publication. For more information please visit 
our Online First Fact Sheet 





















































Pathogenesis of SLE and LN 
A complex interplay between immunological, genetic, hormonal and environmental 
factors is thought to account for the development of SLE.1  
Figure below show the interaction of environmental,immunological and genetic 
factors in SLE 
 
Self-nuclear antigen exposure from defective dead cell clearance result in loss of 
immune tolerance and lifelong persistence of ANA antibodies, indicating persistently 
active autoreactive T and B cell clones1, 2. 
3.5 Role of Genetic factors in Pathogenesis 
Evidence for genetic component in SLE is provided for by: 
▪ High heritability in twin studies, siblings and first and second-degree relatives 
with SLE. 
▪ Emerging data from Genome Wide Association Studies.3 
▪ Some polymorphisms in immunoglobulin receptor alleles present on 
macrophages, have been associated with susceptibility to lupus nephritis in 
some studies.4, 5 


















There appears to be an understanding that there may be a background genetic 
abnormality to predispose an individual to developing SLE.3 
Figure below summarise the cellular mechanism leading to autoantibody production 
.  
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LOSS OF IMMUNE TOLERANCE
Defective dead cell clearance because of impaired 
apoptosis,opsonization of dead cells by complement,
or their removal by phagocytes.












Mechanisms of Kidney Damage in Lupus 
Immune complex deposition in the kidneys plays a pivotal role in LN. These 
immune deposits occur in the mesangium, sub endothelium, or sub epithelium 
depending on the characteristics of both the antigen and antibody. The intrarenal 
aetiology of lupus nephritis involves antibody binding to multiple intrarenal 
autoantigens rather than the deposition of circulating immune complexes.1 
The site of binding or deposition is determined by size or charge of the immune 
complexes. Large intact immune complexes or anionic antigens which cannot cross 
the negative charge barrier in the glomerular capillary wall are deposited in the 
mesangium and sub endothelial space.2, 3 
On the other hand, sub epithelial deposits may form when a cationic antigen crosses 
the GBM or an autoantibody directed against epithelial cell antigens. 
These immune complexes are mainly due to anti-double-stranded DNA antibodies 
directed against nucleosomes.4These immune complexes may also contain 
chromatin, C1q, laminin, Sm, La (SS-B), Ro (SS-A), ubiquitin, and ribosomes.5-7 
3.7 Sub endothelial or Mesangial deposits 
Deposits that occur in the mesangium and sub endothelium are in communication 
with the vascular space since they are proximal to the GBM. 
Thus, complement is activated generating chemo attractants C3a and C5a resulting 
in the influx of neutrophils and mononuclear cells. These changes manifest 
histologically by a mesangial, focal or diffuse proliferative glomerulonephritis. This 
manifests clinically as an active urine sediment, proteinuria, and in some cases acute 
decline in renal function. 




3.8 Sub Epithelial deposits 
Sub epithelial deposits are separated from the circulation by the GBM hence the  
inflammatory response is minimal  and injury is limited3. The injury is limited to the 
glomerular epithelial cells and the primary clinical manifestation is proteinuria, 
which is often in the nephrotic range. Histologically, these patients most commonly 
have membranous nephropathy. 
Figure 2.8 
 
3.9 IgG subclass in Sub Epithelial or Sub endothelial deposits 
Further evidence to support this delineation can be found by analysing the 
distribution of the IgG subclasses in the immune complexes. Sub class IgG1 and IgG3 
fix complement, while IgG2 does so less avidly and IgG4 does not fix complement.9 
Consistent with this hypothesis are the observations that anti-DNA antibodies 
associated with diffuse proliferative glomerulonephritis hence sub endothelial tend 
to be IgG1 and IgG3.10 On the other hand the immune deposits in membranous 
nephropathy thus sub epithelial are more likely to be IgG2 and IgG4.11 
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Appendix 9:Definition of relapses/Flare of LN.1 
*high power field
1. KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney
International Supplements. 2012; 2: 209.
Mild kidney relapse Moderate kidney relapse Severe kidney relapse 
Increase in glomerular 
haematuria 




recurrence of ≥1 RBC cast, 
WBC 
cast (no infection), or both 
If baseline creatinine is: 
<177 umol/l, an increase of 17.7–88.4 
umol/l 
>177 umol/l], an increase of 35.4–132.6
umol/l
AND/OR 
If baseline uPCR is: 
< 500 mg/g an increase to >1000 mg/g 
500–1000 mg/g, an increase to 
≥2000 mg/g, but less than absolute 
increase of < 5000 mg/g  
>1000 mg/g, an increase of ≥2-fold
with absolute uPCR < 5000 mg/
If baseline creatinine is: 
< 177 umol/l, an increase of 
>88.4 mmol/
≥ 177 mmol/l, an increase 
of > 132.6 mmol/l 
AND/OR 
an absolute increase of 
uPCR > 5000 mg/g 
